For all of us who work in an HIV-relevant field, the learning never ends. Science is an ocean, and we're constantly feeding it with rivers of new research.
Once you've read through this week's selection of recently published HIV-related studies, you'll know a little more than you did yesterday about:
- The promise of lamivudine/raltegravir as a future pre-exposure prophylaxis (PrEP) option.
- The potential impact of a feminizing hormone on PrEP efficacy.
- The gentler renal profile of new tenofovir (TAF) compared to old tenofovir (TDF).
- The role internet dating plays in HIV incidence.
Come aboard and sail the research-driven seas with us. To beat HIV, you have to follow the science!